OPEN ACCESS

Check for updates

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

Joshua D Wallach,^{1,2} Kun Wang,³ Audrey D Zhang,^{3,4} Deanna Cheng,⁵ Holly K Grossetta Nardini,⁶ Haiqun Lin,⁷ Michael B Bracken,⁵ Mayur Desai,⁵ Harlan M Krumholz,^{3,8,9} Joseph S Ross^{2,3,9,10}

For numbered affiliations see end of the article.

Correspondence to: J D Wallach
joshua.wallach@yale.edu
(or @JoshuaDWallach on Twitter
ORCID 0000-0002-2816-6905)

Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2020;368:l7078
<http://dx.doi.org/10.1136/bmj.l7078>

Accepted: 10 December 2019

ABSTRACT

OBJECTIVES

To conduct a systematic review and meta-analysis of the effects of rosiglitazone treatment on cardiovascular risk and mortality using multiple data sources and varying analytical approaches with three aims in mind: to clarify uncertainties about the cardiovascular risk of rosiglitazone; to determine whether different analytical approaches are likely to alter the conclusions of adverse event meta-analyses; and to inform efforts to promote clinical trial transparency and data sharing.

DESIGN

Systematic review and meta-analysis of randomized controlled trials.

DATA SOURCES

GlaxoSmithKline's (GSK's) ClinicalStudyDataRequest.com for individual patient level data (IPD) and GSK's Study Register platforms, MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Registry of Controlled Trials, Scopus, and ClinicalTrials.gov from inception to January 2019 for summary level data.

ELIGIBILITY CRITERIA FOR SELECTING STUDIES

Randomized, controlled, phase II-IV clinical trials that compared rosiglitazone with any control for at least 24 weeks in adults.

DATA EXTRACTION AND SYNTHESIS

For analyses of trials for which IPD were available, a composite outcome of acute myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death was examined.

These four events were examined independently as secondary analyses. For analyses including trials for which IPD were not available, myocardial infarction and cardiovascular related death were examined, which were determined from summary level data. Multiple meta-analyses were conducted that accounted for trials with zero events in one or both arms with two different continuity corrections (0.5 constant and treatment arm) to calculate odds ratios and risk ratios with 95% confidence intervals.

RESULTS

33 eligible trials were identified from ClinicalStudyDataRequest.com for which IPD were available (21 156 patients). Additionally, 103 trials for which IPD were not available were included in the meta-analyses for myocardial infarction (23 683 patients), and 103 trials for which IPD were not available contributed to the meta-analyses for cardiovascular related death (22 772 patients). Among 29 trials for which IPD were available and that were included in previous meta-analyses using GSK's summary level data, more myocardial infarction events were identified by using IPD instead of summary level data for 26 trials, and fewer cardiovascular related deaths for five trials. When analyses were limited to trials for which IPD were available, and a constant continuity correction of 0.5 and a random effects model were used to account for trials with zero events in only one arm, patients treated with rosiglitazone had a 33% increased risk of a composite event compared with controls (odds ratio 1.33, 95% confidence interval 1.09 to 1.61; rosiglitazone population: 274 events among 11 837 patients; control population: 219 events among 9319 patients). The odds ratios for myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death were 1.17 (0.92 to 1.51), 1.54 (1.14 to 2.09), 1.15 (0.55 to 2.41), and 1.18 (0.60 to 2.30), respectively. For analyses including trials for which IPD were not available, odds ratios for myocardial infarction and cardiovascular related death were attenuated (1.09, 0.88 to 1.35, and 1.12, 0.72 to 1.74, respectively). Results were broadly consistent when analyses were repeated using trials with zero events across both arms and either of the two continuity corrections was used.

CONCLUSIONS

The results suggest that rosiglitazone is associated with an increased cardiovascular risk, especially for heart failure events. Although increased risk of myocardial infarction was observed across analyses, the strength of the evidence varied and effect

WHAT IS ALREADY KNOWN ON THIS TOPIC

Since 2007, several meta-analyses have been conducted that have used various analytic approaches and reported conflicting findings about the cardiovascular risk of rosiglitazone

Previous meta-analyses did not have access to individual patient level data (IPD) from clinical trials and mostly relied on summary level data

Little consensus exists on which method should be used to account for sparse adverse event data in meta-analyses

WHAT THIS STUDY ADDS

Among trials for which IPD were available, rosiglitazone use was consistently associated with an increased cardiovascular risk, especially for heart failure events

Increased myocardial infarction risk was observed across analyses, but the magnitudes of risk varied and were attenuated when summary level data were used in addition to IPD

Among trials for which IPD were available, more myocardial infarctions and fewer cardiovascular deaths were reported in IPD compared with summary level data

estimates were attenuated when summary level data were used in addition to IPD. Because more myocardial infarctions and fewer cardiovascular related deaths were reported in the IPD than in the summary level data, sharing IPD might be necessary when performing meta-analyses focused on safety.

SYSTEMATIC REVIEW REGISTRATION

OSF Home <https://osf.io/4yvp2/>.

Introduction

Rosiglitazone is manufactured by GlaxoSmithKline (GSK) under the brand name Avandia. In 1999, the Food and Drug Administration (FDA) in the United States first approved this drug to treat type 2 diabetes mellitus.^{1 2} Although the European Medicines Agency initially rejected the drug in 1999, market authorization was granted in Europe in 2000.³ Despite regulatory warnings for heart failure,³ use of rosiglitazone grew rapidly and annual sales peaked at approximately \$3.3bn (£2.5bn; €2.9bn) in 2006.⁴ However, in May 2007 a meta-analysis of 42 GSK trials suggested a 43% increased risk of myocardial infarction.⁵ The ensuing discussion in the media and the peer reviewed literature resulted in widespread awareness of the cardiovascular safety concerns about rosiglitazone. These findings, which led to questions about why the European Medicines Agency approved rosiglitazone³ and whether GSK and the FDA should have released similar information earlier, resulted in congressional hearings and an FDA safety alert.⁶⁻⁸ In 2007 the European Medicines Evaluation Agency recommended new warnings for patients with ischemic heart disease, and by 2010 rosiglitazone was suspended from European markets owing to cardiovascular risks.³

Between 2010 and 2011, the FDA updated rosiglitazone's product label to include information on cardiovascular risks and limited the availability of the drug as part of a Risk Evaluation Mitigation Strategy (REMS) programme, where patients could only receive rosiglitazone from specialty mail order pharmacies.^{2 9} The restrictions were withdrawn in 2013 after an analysis of the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) study found that rosiglitazone's cardiovascular safety profile did not differ from that of other drugs used for diabetes management (eg, sulfonylurea).¹⁰ However, the design and conduct of the RECORD study were widely criticized, and apprehension seems to remain among patients and physicians about use of the drug.^{11 12} Although rosiglitazone has been removed from the market in most countries,³ and use in the US has rapidly dropped

since boxed warnings were issued in 2007,^{13 14} the drug is still available in the US.

Since 2007, several meta-analyses have been conducted that have used various analytic approaches and reported conflicting findings about rosiglitazone's cardiovascular risk. According to UpToDate, an online clinical decision support resource, the use of rosiglitazone is currently not recommended because of concerns "about its atherogenic lipid profiles and a potential increased risk for cardiovascular events."¹⁵ However, UpToDate also notes that "the effect of rosiglitazone on the risk of MI [myocardial infarction] is uncertain."¹⁵ Some of this uncertainty about rosiglitazone's cardiovascular risk might be caused by limitations in previous meta-analyses and in the original trial designs.¹⁶⁻²¹

Firstly, previous systematic reviews and meta-analyses relied on GSK summary level data and publication level data.^{5 21} Since the approval of rosiglitazone and the original meta-analyses were published, dozens of additional trials have been published. Moreover, the meta-analyses did not have access to individual patient level data (IPD), which are raw data from clinical trial participants (table 1). Unlike publicly available summary level data sources, which often report only composite study outcomes and rarely summarize safety events,^{22 23} IPD can be used to more consistently identify events,²⁴⁻²⁶ classify and evaluate individual or composite adverse events, and determine potentially missing or poorly reported outcomes. These characteristics might help minimize the impact of selective adverse event reporting in publications.²⁴

Secondly, many reviews used meta-analytic approaches that excluded trials with zero events in the treatment and control groups,^{5 21} even though these studies suggest that, at least in a clinical trial population, certain outcomes occur infrequently. While trials with zero events do not provide information about the direction or magnitude of relative treatment effects, arguments have been made that the inclusion of these trials in meta-analyses can lead to more precise effect estimates.^{17 18 27-30}

Initiatives to promote open science and data sharing,^{25 31 32} including recent efforts by GSK to make IPD available to external investigators for research that can help advance medical science or improve patient care,³³ present a unique opportunity to better address the concerns about rosiglitazone's cardiovascular risk. Our objective was to determine the effects of rosiglitazone treatment on cardiovascular risk and mortality. We conducted a comprehensive systematic

Table 1 | Examples of data sources for meta-analyses

Summary or aggregate level data				Individual patient level data
Published literature	Registries	Clinical study reports		
Publications, available through publication databases, provide aggregate results, including effect estimates, measures of precision, or adverse event counts observed in treatment arms and comparator arms	Registries are online databases that report information about timing, design, and results of clinical trials (eg, ClinicalTrials.gov). Results reported on registries often include summary effect estimates or adverse event counts	Clinical study reports are detailed documents that describe design and results of clinical trials. Full reports include efficacy and safety data, but do not provide patient specific information		Raw data from individual participants in clinical trials

review and meta-analysis of all trials for which IPD were available from GSK's rosiglitazone clinical trial programme, and we used supplemental summary level data when IPD data were not available. We intended to advance knowledge in three main areas. Firstly, to clarify uncertainties about the cardiovascular risk of rosiglitazone among clinicians, patients, and policy makers. We combined trials identified through different data sources and considered several analytical methods to better estimate the effects of rosiglitazone on cardiovascular risk and mortality. We also examined the risk of a composite outcome of four events: heart failure, acute myocardial infarction, cardiovascular related deaths, and non-cardiovascular related deaths. This composite outcome was informed by previous meta-analyses and black box warnings.^{5 21} We also examined these four events independently as secondary analyses.

Secondly, we aimed to determine whether different analytical approaches are likely to alter the conclusions of adverse event meta-analyses. Meta-analyses of adverse event data involve analytical complexities, such as estimating effects from trials with zero events in one or both treatment arms. Our work could elucidate whether common analytical approaches that have been proposed to account for sparse data could alter conclusions about rosiglitazone, potentially guiding future safety focused meta-analyses.

Finally, our analysis could help to promote clinical trial transparency and trial data sharing initiatives, including the role of IPD in meta-analyses of drug safety. Overall, the findings from this study could inform how diabetes drugs are approved and how data sources and methods should be considered when monitoring the safety of drugs in the postmarket setting.³⁴

Methods

This systematic review and meta-analysis is reported according to the preferred reporting items for systematic reviews and meta-analyses IPD (PRISMA-IPD) statement.^{35 36} The original proposal for the IPD portion of the study and study protocol is available online: <https://osf.io/4yvp2/>.

Search strategy and data sources

Clinical trial data on the effects of rosiglitazone treatment on cardiovascular risk and mortality might be reported in multiple public and non-public sources.³⁷ We first identified and requested all phase II, III, and IV clinical trials of rosiglitazone with IPD made available by GSK through ClinicalStudyDataRequest.com (CSDR). CSDR was developed by GSK as a system for providing access to patient level data from clinical trials.³³ CSDR allows independent researchers to request clinical trial IPD from over 1500 studies. We then reviewed the references included in three previous meta-analyses that focused on rosiglitazone and identified 220 candidate trials for inclusion.^{5 21 38} On 3 May 2017, we searched "rosiglitazone" in the "interventional/treatment" field of ClinicalTrials.gov, a registry of clinical trials run by the US National Library of Medicine, and identified 220 entries. We then performed a full text search for

"rosiglitazone," limited to phase II-IV trials, on GSK Study Register (gsk-clinicalstudyregister.com). The GSK Study Register is a repository of data and information about GSK studies, which includes protocol summaries, scientific results summaries, protocols, and clinical study reports. The final search retrieved a total of 150 entries with scientific result summaries.

Database searches

We performed a systematic literature search in accordance with the PRISMA statement to identify all published phase II, III, and IV clinical trials for which IPD or clinical study reports were not available. An experienced medical librarian (HKGN) consulted on methods and ran a medical subject heading analysis of known key articles provided by the research team (mesh.med.yale.edu).³⁹ In each database, we ran scoping searches and used an iterative process to translate and refine the searches. The formal search used minimal controlled vocabulary terms and synonymous free text words plus the CAS registry number to maximize sensitivity and to capture the concepts of "rosiglitazone" and "Avandia." We combined this set with the concept of clinical trials using the Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE.

On 13 December 2017, the librarian performed a comprehensive search of multiple databases: MEDLINE (Ovid ALL, from 1946 to December week 1 2017), PubMed for in-process and unindexed material, Embase (Ovid, from 1974 to 13 December 2017), Web of Science, Science Citation Index Expanded (Thompson Reuters, all years), Cochrane Central Registry of Controlled Trials (Wiley, issue 12 of 12, December 2017), and Scopus (Elsevier, all years). English and foreign language articles were eligible for inclusion. No date limit was applied. The search retrieved a total of 5629 references, which we pooled in EndNote and deduplicated (<https://www.endnote.com/>).⁴⁰ We uploaded this set to Covidence (<https://www.covidence.org/>),⁴¹ which identified additional duplicates, leaving 4774 for screening. On 31 January 2019, all searches were updated and an additional 162 records were added to Covidence and screened. In all, we retrieved 6049 studies across all databases and dates, and screened 4604 studies. Supplementary appendix box 1 summarizes all the search strategies, and figure 1 and figure 2 present PRISMA flowcharts.

Finally, for all published articles with unclear adverse events reported, we sent individual emails that referenced the specific population of interest, outlined the number of relevant adverse events reported in the publication, and asked the authors to verify whether the abstracted values were correct. Because public sources such as journals and trial registrations are more likely to be incomplete,^{37 42} we prioritized the information reported in IPD and clinical study reports. However, we only requested IPD for studies made available through CSDR.

Eligibility criteria

We included all randomized controlled trials that compared the effect of rosiglitazone with any control

Fig 1 | Modified PRISMA (preferred reporting items for systematic reviews and meta-analyses) flowchart of search showing trials identified through literature search, trials requested from GSK CSDR.com, and those identified through GSK Study Register. CSDR.com=ClinicalStudyDataRequest.com; GSK=GlaxoSmithKline

Fig 2 | Modified PRISMA (preferred reporting items for systematic reviews and meta-analyses) flowchart of search showing trials identified in previous meta-analyses and on ClinicalTrials.gov. CSDR.com=ClinicalStudyDataRequest.com; GSK=GlaxoSmithKline

group. We excluded studies that had less than 24 weeks of drug use (previous meta-analyses have used similar criteria^{5 21}); studies that had no comparator arms; studies that focused on pediatric patient populations; those that were terminated early, unless they were stopped after 24 weeks or longer, or they were stopped for cardiovascular related safety reasons; extension studies when it was unclear whether patients switched treatment groups; studies that had non-clinical study designs (eg, animal studies or trials with healthy participants); and those that were presentations or abstracts without adverse events.

Study selection

Three reviewers (JDW, DC, JSR) screened all of the records identified on CSDR and one independent reviewer (JDW) screened all other records at the title and abstract level. Potentially eligible studies were assessed in full text by two reviewers (JDW, ADZ), with arbitration by a third reviewer (JSR). When multiple publications of one study were retrieved, we used data from the report with the longest duration of follow-up. For each potentially eligible trial identified, we determined overlapping ClinicalTrials.

gov registrations, publications, clinical study reports, and IPD. When sponsor or funder trial identifiers, or ClinicalTrials.gov national clinical trial identifiers were provided, we used those to match trials reported across multiple sources. When publications had corresponding ClinicalTrials.gov registrations with reported results, we abstracted data from the source with the greatest number of events. However, if a publication or registration had IPD or a corresponding GSK Clinical Study ID on gsk-clinicalstudyregister.com, we prioritized the IPD and then the clinical study report or scientific result summary data.

Data collection and analysis

For all included studies, we either used the demographic and study design characteristics provided in publications, or when available, data provided by GSK or on ClinicalTrials.gov registries. We recorded the intention to treat population, average age, proportion male, and proportion white race for each treatment arm. We also recorded the treatment regimen, treatment dosage, treatment duration, and relevant adverse events. Groups of patients who received any dosage of rosiglitazone were pooled together to make

up the treatment group. The control group was defined as patients who received any drug regimen other than rosiglitazone, including placebo.

Individual patient level data

The outcomes selected for this meta-analysis were informed by the previous meta-analyses and black box warnings.^{5 21} The primary outcome for the trials for which IPD were available was the composite of four cardiovascular risk and mortality outcomes: acute myocardial infarction events, heart failure events, cardiovascular related deaths, and non-cardiovascular related deaths. We examined these four events independently as secondary analyses. All clinical trials conducted by GSK used the Medical Dictionary for Regulatory Activities (MedDRA) terms to report trial adverse events (supplementary appendix box 2). MedDRA is the international medical terminology developed under the guidance of the International Conference of Technical Requirements for Registration of Pharmaceuticals for Human Use.⁴³ Four authors (JDW, DC, KW, JSR) reviewed all adverse event listings and abstracted data from the adverse event tabulations to identify acute myocardial infarctions, heart failures, deaths from cardiovascular related cause, and deaths from non-cardiovascular related cause. Trials made available by GSK through CSDR were excluded if they did not report “high level” or “preferred” adverse event terms because our outcomes of interest could only be derived from their use.

Summary data

For trials for which IPD were not available, we focused on myocardial infarction and cardiovascular related deaths (determined by any cardiac cause, cerebrovascular disease, sudden death, cardiac arrest of unspecific origin, or peripheral artery disease) because of reporting limitations in publications and clinical study reports. We excluded articles that failed to mention a specific adverse event of interest and also those that did not disclose that serious adverse events were not observed. These exclusions applied unless additional information was provided by the corresponding authors, even though failure to mention a particular outcome does not necessarily imply that there were no such events in the study.

Assessment of risk of bias in included studies and validation

Two reviewers (JDW, ADZ) assessed the risk of bias based on the Cochrane Collaboration risk of bias assessment tool (supplementary appendix box 3). For validation, supplementary appendix tables 1 and 2 note the specific outcome classification for a subset of trials for which IPD were available that were also included in previously conducted meta-analyses.

Statistical analysis

We prespecified a series of two stage meta-analyses that account for different data sources and various analytical approaches because we combined results

from trials with and without IPD (table 2). In the first stage, we calculated trial specific odds ratios or relative risks and their corresponding 95% confidence intervals. In the second stage, effect estimates from each individual trial were combined by fixed or random effects meta-analysis models. We also used Peto's method to pool odds ratios because this was the method reported in the original rosiglitazone meta-analysis.⁵ Peto's method is often the standard method for meta-analyses with rare events and small intervention effects.^{16 44} While this method does not require correction for trials in which one arm has no events (single zero event trials), the method performs best when event rates are low (<1%) and the treatment arm allocations are balanced.⁴⁵ Previous studies have noted that substantial imbalance exists in the number of patients in many of the rosiglitazone trials.⁴⁴ We then combined the results from each individual trial using conventional fixed (Mantel-Haenszel) or random (Dersimonian and Laird) effects methods (table 2). We repeated all analyses by including single zero event trials and trials with zero events in both arms (total zero event trials), and we applied two different continuity corrections: a constant continuity correction, which adds 0.5 to each cell in a 2×2 contingency table for the trials with at least one zero event; and a treatment arm continuity correction, when values proportionate to the reciprocal of the size of the opposite treatment group are added to each cell.

We considered four different combinations of data sources: IPD only; IPD and the RECORD study; IPD and the summary level data (clinical study reports, data from previous meta-analyses, and publications or ClinicalTrials.gov registrations); and IPD, the summary level data, and the RECORD study. Although the RECORD study included observational follow-up of a clinical trial, which fails to meet our prespecified inclusion criteria, RECORD data were used to inform the easing of restrictions of the rosiglitazone REMS and are therefore an important source of evidence.^{11 21 46 47} Previous studies have noted that the Peto odds ratio is not recommended when there is substantial imbalance in the number of patients and inverse variance methods perform poorly when data are sparse.^{16 44} Therefore, we focused our reporting on odds ratios by using a constant continuity correction of 0.5 and random effects weighting procedures. We assessed heterogeneity between trials by using the I^2 statistic.

Sensitivity analyses

A large number of approaches have been proposed to analyze sparse data in meta-analyses. We selected and prioritized the approaches that are most likely to be included in meta-analytical software and therefore used in future evaluations.^{17 30 44 45 48 49} However, as suggested during peer review, we also evaluated whether one stage generalized fixed and random study specific models (the Simmonds and Higgins model with random study specific effects using the lme4 package in R) produced effect estimates and 95% confidence intervals that were consistent with the two

Table 2 | Primary analytical methods, continuity corrections, assumptions, and outcomes

Method, measure, effect type, and data sources	Single zero event trials	Zero total event trials	Continuity correction	Assumptions to satisfy or difficulties to consider	Outcomes
Peto, odds ratio, fixed effect					
IPD only, IPD+RECORD, IPD+summary, IPD+summary+RECORD	Included	Excluded	None	Event rates <1%, balanced groups (treatment arms), small/moderate treatment effects	Analyses with IPD only: composite outcome, heart failure, myocardial infarction, cardiovascular related deaths, non-cardiovascular related deaths Analyses including summary data: myocardial infarction, cardiovascular related deaths
Mantel-Haenszel or Dersimonian and Laird (inverse variance), odds ratio or relative risk, fixed or random effects					
IPD only, IPD+RECORD, IPD+summary, IPD+summary+RECORD	Included	Excluded or Included	Constant continuity correction of 0.5 or treatment arm continuity correction	Sample must be "large" overall (crude totals across all studies need to be ≥ 5), ⁴⁴ might perform comparably or better than Peto's method at even rates of 5-10% ⁴⁴	Analyses with IPD only: composite outcome, heart failure, myocardial infarction, cardiovascular related death, non-cardiovascular related deaths Analyses including summary data: myocardial infarction, cardiovascular related deaths

IPD=individual patient level data; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study.

stage models.⁵⁰ One stage approaches have certain advantages, for example they do not require continuity corrections. However, simulations and evaluations suggest that one stage and two stage approaches can give similar results, and differences are often influenced by modeling assumptions.⁵¹

We also conducted four post hoc subgroup analyses (constant continuity correction of 0.5 and random effects weighting procedures), which included and excluded total zero event trials: indication (type 2 diabetes mellitus *v* other) for all outcomes; trial duration (<26 weeks, 26-48 weeks, >48 weeks); data source (IPD, clinical study reports, or previous meta-analyses *v* published articles or ClinicalTrials.gov registrations) for myocardial infarction and cardiovascular related deaths; and comparator (placebo, metformin, sulfonylureas *v* other) for all outcomes. Because of the large number of proposed analyses and our focus on evaluating the impact of using different data sources, regardless of trial size, and various statistical techniques, additional sensitivity analyses that excluded trials based on their risk of bias were outside the scope of this evaluation. As suggested during peer review, we investigated whether Hartung-Knapp confidence interval corrections would alter the conclusions of the primary meta-analyses for the composite outcome with constant continuity corrections. We assessed potential publication bias by generating funnel plots and using Egger's test for the analyses using odds ratios with constant continuity corrections.⁵² All statistical analyses were performed by one reviewer (JDW) using the "meta" package in R (version 3.3) and verified by a second statistician (KW).

Patient and public involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results.

Results

Description of included studies

Of the 59 trials identified and requested from the GSK clinical trial registry database, 33 met the inclusion criteria and had IPD (n=34, including the RECORD study which contained observational follow-up data).

We identified an additional 31 eligible trials included in previous meta-analyses (n=26),^{5 21 38} on the GSK Study Register (n=4), and on ClinicalTrials.gov (n=1). Among the 4774 titles and abstracts identified through the literature search, 170 were excluded as duplicates, leaving 4604 for initial screening. We excluded 4331 during the initial screening based on the title and abstract. Among the remaining 273 records screened at the full text level, 193 were excluded, mostly because they represented multiple publications from the same trial, publications from trials for which we already had IPD or clinical study reports, or abstracts without data. We were left with 80 trials that met the initial inclusion criteria, potentially reported outcomes of interest, and which were not available on the GSK database (fig 1 and fig 2). Of these trials, we were able to obtain either myocardial infarction or cardiovascular related death event data for a total of 75 additional included trials.

Among the 33 trials for which IPD were available, there were a total of 21156 patients, over half of whom (11837, 56.0%) received rosiglitazone (dosages ranging from 2 to 8 mg each day). Although most trials enrolled patients with type 2 diabetes mellitus (25 of 33, 75.8%), eight (24.2%) focused on other non-FDA approved (off label) indications (two psoriasis, one rheumatoid arthritis, one atherosclerosis, and four Alzheimer's disease; supplementary appendix table 1). Among 11837 patients allocated to rosiglitazone treatment, there were 274 composite events (2.3%) and 147 myocardial infarctions (1.24%), 122 heart failures (1.03%), 15 cardiovascular related deaths (0.13%), and 22 non-cardiovascular related deaths (0.19%). Among 9319 patients allocated to comparator treatments, there were 219 composite events (2.4%) and 133 myocardial infarctions (1.4%), 80 heart failures (0.86%), 10 cardiovascular related deaths (0.11%), and 13 non-cardiovascular related deaths (0.14%; supplementary appendix table 2). Median trial duration was 24 weeks (interquartile range 24-52 weeks).

Among the 103 trials for which IPD were not available included in the meta-analyses for myocardial infarction, there were a total of 23683 patients, of which 12630 (53.3%) were randomized to rosiglitazone and 11053 (46.7%) to comparator arms. Approximately two thirds of the trials included adult patients with type 2 diabetes mellitus (69, 67.0%). Among the rosiglitazone and

comparator arms, there were 43 (0.34%) and 40 (0.36%) myocardial infarctions, respectively. Median duration was 26 weeks (interquartile range 26-52 weeks). Coincidentally, the same number of trials without IPD contributed to the meta-analyses for cardiovascular death. These trials included 22 772 patients, of which 12 183 (53.5%) were randomized to rosiglitazone and 10 589 (46.5%) to comparator arms. Most trials (71, 68.9%) enrolled patients with type 2 diabetes mellitus. Among the rosiglitazone and comparator arms, there were 26 (0.21%) and 20 (0.19%) cardiovascular related deaths, respectively (supplementary appendix table 2). Median trial duration was 26 weeks (interquartile range 26-52 weeks).

Comparing IPD and summary level data

We identified 29 trials for which IPD were available and that were included in previous meta-analyses using GSK's summary level data. Among these, three trials had the same number of myocardial infarction events reported in both sources and 23 trials had the same number of cardiovascular related deaths (supplementary appendix table 2). However, we identified more myocardial infarction events using IPD instead of summary level data for 26 trials, and more cardiovascular related deaths for one trial. The IPD contained fewer myocardial infarctions than reported through GSK's summary level data for only one trial, however fewer cardiovascular related deaths were reported for five trials. Finally, the IPD for the RECORD study contained more myocardial infarctions and fewer cardiovascular related deaths than reported in GSK's summary level data.

After the analysis was complete, we were alerted to discrepancies in the number of fatal adverse events between the event numbers reported in this study and in other reports for four of the 34 trials for which IPD were used (ADOPT, AVA102670, AVA102672, and AVD100521). For three of the 34 trials (AVA102670, AVA102672, and AVD100521), the number of fatal events differed by 28, 24, and 11, respectively. For the 34th trial, ADOPT, the clinical study report redacted all information on causes of death, but the overall number of deaths differed greatly from the total number of deaths that we identified using the originally shared IPD (96 v 5). Because of the large number of meta-analyses conducted and presented in this paper—each including varying numbers of trials and data types (individual patient level data v summary data), examining multiple different endpoints, and using an array of statistical approaches—the investigators and editors determined that only the primary analysis would be repeated using the alternate number of events, finding that the conclusions regarding cardiovascular specific and mortality risk associated with rosiglitazone were not meaningfully different (web table).

Meta-analyses

IPD trials

We found a 33% increased odds of a composite event (that is, myocardial infarction events, heart failure

events, cardiovascular related deaths, and non-cardiovascular related deaths) among rosiglitazone arms compared with comparator arms (odds ratio 1.33, 95% confidence interval 1.09 to 1.61, $P=0.005$, $I^2=0$; 31 single zero event trials; random effects and continuity correction 0.5; table 3). The effect estimate and 95% confidence interval did not change when total zero event trials were included (1.33, 1.09 to 1.61, $P=0.005$, $I^2=0$; 33 total zero event trials; random effects and continuity correction 0.5; table 3). When each of the four outcomes was examined independently, the odds ratios were 1.17 (0.92 to 1.51, $I^2=0$; 30 single zero event trials; random effects and continuity correction 0.5; table 4) for myocardial infarction; 1.54 (1.14 to 2.09, $P=0.005$, $I^2=0$; 26 single zero event trials; random effects and continuity correction 0.5; table 5) for heart failure; 1.15 (0.55 to 2.41, $I^2=0$; 16 single zero event trials; random effects and continuity correction 0.5; table 6) for cardiovascular related death; and 1.18 (0.60 to 2.30, $I^2=0$; 16 single zero event trials; random effects and continuity correction 0.5; table 7) for non-cardiovascular related death. Although all effect estimates were attenuated towards the null when we included the RECORD trial and total zero event trials with 0.5 continuity corrections, effect estimates were consistently larger when we applied treatment arm continuity corrections.

Meta-analysis using all trials

Across all data sources, rosiglitazone was associated with a 9% increased odds of myocardial infarction (odds ratio 1.09, 95% confidence interval 0.88 to 1.35, $I^2=0$; 60 single zero event trials; random effects and continuity correction 0.5; table 4). When we considered all 136 trials (33 from IPD and 103 from clinical summary reports or previous meta-analyses, and publications or ClinicalTrials.gov registrations), including single zero event and total zero event trials, the odds ratio was 1.08 (0.89 to 1.31, $I^2=0$; 136 single zero event and zero total event trials; random effects and continuity correction 0.5; table 4). Rosiglitazone was associated with a 12% increased odds of cardiovascular related deaths (1.12, 0.72 to 1.74, $I^2=0$; 33 single zero event trials; random effects and continuity correction 0.5; table 6). Across all 136 single zero event and total zero event trials, we found no association between rosiglitazone and death from cardiovascular related causes (1.00, 0.74 to 1.33, $I^2=0$; 136 single zero event and zero total event trials; random effects and continuity correction 0.5; table 6). Similar to the analyses limited to IPD, effect estimates were larger (more harmful) when we applied treatment arm continuity corrections. Forest plots for the primary analyses are available online at <https://osf.io/4yvp2/>. All I^2 and τ^2 values were 0.0.

Sensitivity analyses

The effect estimates and 95% confidence intervals from one stage analyses were consistent with those from two stage analyses (table 8). We found no statistically significant differences in the post hoc subgroup analyses for indication (type 2 diabetes

Table 3 | Rosiglitazone meta-analyses for composite outcome

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	P value	No of trials
Peto (fixed)						
IPD only	Included	Excluded	None	OR 1.40 (1.16 to 1.69)	0.000	31
IPD+RECORD	Included	Excluded		OR 1.20 (1.06 to 1.36)	0.004	32
Mantel-Haenszel (fixed)						
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.39 (1.15 to 1.68)	0.001	31
				RR 1.37 (1.14 to 1.64)	0.001	31
IPD+RECORD	Included	Excluded		OR 1.20 (1.06 to 1.36)	0.005	32
				RR 1.17 (1.05 to 1.31)	0.005	32
IPD only	Included	Included		OR 1.39 (1.15 to 1.68)	0.001	33
				RR 1.36 (1.14 to 1.63)	0.001	33
IPD+RECORD	Included	Included		OR 1.20 (1.06 to 1.36)	0.005	34
				RR 1.17 (1.05 to 1.31)	0.005	34
Dersimonian and Laird (random)						
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.33 (1.09 to 1.61)	0.005	31
				RR 1.30 (1.08 to 1.56)	0.005	31
IPD+RECORD	Included	Excluded		OR 1.17 (1.03 to 1.33)	0.02	32
				RR 1.14 (1.02 to 1.28)	0.02	32
IPD only	Included	Included		OR 1.33 (1.09 to 1.61)	0.005	33
				RR 1.30 (1.08 to 1.56)	0.005	33
IPD+RECORD	Included	Included		OR 1.17 (1.03 to 1.33)	0.02	34
				RR 1.14 (1.02 to 1.28)	0.02	34
Mantel-Haenszel (fixed)						
IPD only	Included	Excluded	Treatment arm correction	OR 1.41 (1.16 to 1.70)	0.001	31
				RR 1.38 (1.15 to 1.65)	0.001	31
IPD+RECORD	Included	Excluded		OR 1.20 (1.06 to 1.36)	0.004	32
				RR 1.18 (1.05 to 1.32)	0.004	32
IPD only	Included	Included		OR 1.40 (1.16 to 1.70)	0.001	33
				RR 1.38 (1.15 to 1.65)	0.001	33
IPD+RECORD	Included	Included		OR 1.20 (1.06 to 1.36)	0.004	34
				RR 1.18 (1.05 to 1.32)	0.004	34
Dersimonian and Laird (random)						
IPD only	Included	Excluded	Treatment arm correction	OR 1.33 (1.09 to 1.61)	0.005	31
				RR 1.30 (1.08 to 1.56)	0.005	31
IPD+RECORD	Included	Excluded		OR 1.17 (1.03 to 1.33)	0.02	32
				RR 1.14 (1.02 to 1.28)	0.20	32
IPD only	Included	Included		OR 1.33 (1.09 to 1.61)	0.005	33
				RR 1.30 (1.08 to 1.56)	0.005	33
IPD+RECORD	Included	Included		OR 1.17 (1.03 to 1.33)	0.02	34
				RR 1.14 (1.02 to 1.28)	0.02	34

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of composite events observed among the total population of patients were as follows: IPD only, rosiglitazone population: 274 events among 11 837 patients; IPD only, control population: 219 events among 9319 patients; RECORD, rosiglitazone population: 333 events among 2226 patients; RECORD, control population: 316 events among 2232 patients.

mellitus *v* other); trial duration (≤ 26 weeks, 26–48 weeks, >48 weeks); data source (IPD *v* other); or comparator (placebo, sulfonylureas, metformin *v* other; data available online at <https://osf.io/4yvp2>). Among the trials for which IPD and summary level data were available, effect estimates and 95% confidence intervals were broadly consistent, regardless of whether we used the IPD or summary level data, or which statistical approach was used (supplementary appendix tables 3 and 4).

When we limited our analyses to only include trials with IPD, we found visual and statistical evidence of asymmetry. However, when we considered all data sources, no visual asymmetry or statistical indication of publication bias was identified (funnel plots are available online at <https://osf.io/4yvp2>). Hartung-Knapp confidence interval corrections did not alter the conclusions of the primary meta-analyses for the composite outcome (supplementary appendix table 5).

Quality assessment

Among the 34 trials for which IPD were available (including the RECORD study), most had a low risk of bias for sequence generation (33, 97.1%); allocation concealment (33, 97.1%); blinding of participants and personnel (30, 88.2%); blinding of outcome assessment (25, 73.5%); and reporting bias (33, 97.1%; supplementary appendix table 6). However, 30 (88.2%) had high or unclear risk of bias for incomplete outcome data. Among the 31 trials that had GSK summary level data, a ClinicalTrials.gov registration, or were included in previous meta-analyses, most had an unclear risk of bias for sequence generation (23, 74.2%); allocation concealment (24, 77.4%); blinding of participants and personnel (15, 48.4%); and blinding of outcome assessment (29, 93.5%). Eighteen (58.1%) had a high risk of bias for incomplete outcome data and 30 (96.7%) had a low risk of bias for reporting bias.

Finally, among the 75 articles (reporting on 76 trials) we identified through the literature search and for which summary data were available, 42 (56.0%), 50 (66.7%), 28 (37.3), 59 (78.7%), 22 (29.3%), and 62 (82.7%) had an unclear risk of bias for sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome

assessment, incomplete outcome data, and reporting bias, respectively.

Discussion

We used multiple clinical trial data sources and different analytical methods in this comprehensive meta-analysis to evaluate the effect of rosiglitazone

Table 4 | Rosiglitazone meta-analyses for myocardial infarction

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	No of trials
Peto (fixed)					
IPD only	Included	Excluded	None	OR 1.30 (1.02 to 1.67)*	30
IPD+RECORD	Included	Excluded		OR 1.17 (0.99 to 1.38)	31
IPD+summary	Included	Excluded		OR 1.19 (0.96 to 1.48)	60
IPD+summary+RECORD	Included	Excluded		OR 1.13 (0.97 to 1.32)	61
Mantel-Haenszel (fixed)					
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.25 (0.99 to 1.60)	30
IPD+RECORD	Included	Excluded		RR 1.25 (0.99 to 1.58)	30
				OR 1.15 (0.98 to 1.36)	31
				RR 1.14 (0.98 to 1.33)	31
IPD+summary	Included	Excluded	OR 1.13 (0.92 to 1.39)	60	
			RR 1.13 (0.92 to 1.38)	60	
IPD+summary+RECORD	Included	Excluded	OR 1.10 (0.95 to 1.28)	61	
			RR 1.10 (0.95 to 1.27)	61	
IPD only	Included	Included	OR 1.25 (0.98 to 1.59)	33	
			RR 1.24 (0.98 to 1.57)	33	
IPD+RECORD	Included	Included	OR 1.15 (0.97 to 1.35)	34	
			RR 1.14 (0.98 to 1.33)	34	
IPD+summary	Included	Included	OR 1.11 (0.92 to 1.34)	136	
			RR 1.11 (0.93 to 1.33)	136	
IPD+summary+RECORD	Included	Included	OR 1.09 (0.95 to 1.26)	137	
			RR 1.09 (0.95 to 1.25)	137	
Dersimonian and Laird (random)					
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.17 (0.92 to 1.51)	30
IPD+RECORD	Included	Excluded		RR 1.16 (0.91 to 1.49)	30
			OR 1.11 (0.94 to 1.32)	31	
			RR 1.10 (0.94 to 1.29)	31	
IPD+summary	Included	Excluded	OR 1.09 (0.88 to 1.35)	60	
			RR 1.09 (0.88 to 1.34)	60	
IPD+summary+RECORD	Included	Excluded	OR 1.08 (0.92 to 1.26)	61	
			RR 1.07 (0.92 to 1.24)	61	
IPD only	Included	Included	OR 1.17 (0.91 to 1.51)	33	
			RR 1.16 (0.91 to 1.48)	33	
IPD+RECORD	Included	Included	OR 1.11 (0.94 to 1.31)	34	
			RR 1.10 (0.94 to 1.29)	34	
IPD+summary	Included	Included	OR 1.08 (0.89 to 1.31)	136	
			RR 1.07 (0.89 to 1.30)	136	
IPD+summary+RECORD	Included	Included	OR 1.07 (0.93 to 1.24)	137	
			RR 1.07 (0.92 to 1.23)	137	
Mantel-Haenszel (fixed)					
IPD only	Included	Excluded	Treatment arm correction	OR 1.29 (1.01 to 1.64)	30
IPD+RECORD	Included	Excluded		RR 1.28 (1.01 to 1.63)	30
				OR 1.16 (0.99 to 1.37)	31
				RR 1.15 (0.99 to 1.35)	31
IPD+summary	Included	Excluded	OR 1.17 (0.96 to 1.44)	60	
			RR 1.17 (0.96 to 1.43)	60	
IPD+summary+RECORD	Included	Excluded	OR 1.12 (0.97 to 1.31)	61	
			RR 1.12 (0.97 to 1.29)	61	
IPD only	Included	Included	OR 1.29 (1.01 to 1.64)	33	
			RR 1.28 (1.01 to 1.62)	33	
IPD+RECORD	Included	Included	OR 1.16 (0.99 to 1.37)	34	
			RR 1.15 (0.99 to 1.35)	34	
IPD+summary	Included	Included	OR 1.14 (0.95 to 1.38)	136	
			RR 1.14 (0.95 to 1.37)	136	
IPD+summary+RECORD	Included	Included	OR 1.11 (0.96 to 1.28)	137	
			RR 1.11 (0.96 to 1.27)	137	

Continued

Table 4 | Continued

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	No of trials
Dersimonian and Laird (random)					
IPD only	Included	Excluded	Treatment arm correction	OR 1.18 (0.92 to 1.53)	30
				RR 1.17 (0.92 to 1.50)	30
IPD+RECORD	Included	Excluded		OR 1.12 (0.94 to 1.32)	31
				RR 1.11 (0.94 to 1.30)	31
IPD+summary	Included	Excluded		OR 1.10 (0.89 to 1.37)	60
				RR 1.10 (0.89 to 1.36)	60
IPD+summary+RECORD	Included	Excluded		OR 1.09 (0.92 to 1.27)	61
				RR 1.08 (0.93 to 1.25)	61
IPD only	Included	Included		OR 1.18 (0.92 to 1.52)	33
				RR 1.17 (0.91 to 1.50)	33
IPD+RECORD	Included	Included		OR 1.12 (0.94 to 1.32)	34
				RR 1.11 (0.94 to 1.30)	34
IPD+summary	Included	Included		OR 1.08 (0.89 to 1.32)	136
				RR 1.08 (0.89 to 1.31)	136
IPD+summary+RECORD	Included	Included		OR 1.08 (0.93 to 1.25)	137
				RR 1.07 (0.93 to 1.23)	137

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of myocardial infarction events observed among total population of patients was as follows: IPD only, rosiglitazone population: 147 events among 11 837 patients; IPD only, control population: 133 events among 9319 patients; RECORD, rosiglitazone population: 167 events among 2226 patients; RECORD, control population: 158 events among 2232 patients; summary, rosiglitazone population: 43 events among 12 630 patients; summary, control population: 40 events among 11 053 patients.

*P=0.04; this was the only significant P value.

on cardiovascular risk and mortality. Among 33 trials for which IPD were available, we observed a 33% increased odds of a composite outcome (that is, myocardial infarction, heart failure, cardiovascular related deaths, and non-cardiovascular related deaths) among patients who received rosiglitazone compared with controls. However, this association was probably partly because of an increased risk of heart failure associated with rosiglitazone. Furthermore, the interpretation of rosiglitazone's cardiovascular risk was complicated by different magnitudes of myocardial infarction risk, which were attenuated by combining summary level data with IPD.

Clarifying uncertainties about the cardiovascular risk of rosiglitazone

Although we observed that rosiglitazone use was associated with an increased cardiovascular risk of approximately 30% among trials for which IPD were available, this could partly be explained by a large increase in the number of heart failure events. This finding is consistent with a previous meta-analysis, which reported an increased risk of heart failure of nearly 70% among those who received rosiglitazone,³⁸ and is consistent with FDA warnings issued in 2001 and 2006.³ However, since 2007, the controversy surrounding rosiglitazone has focused primarily on the possible increased risk of myocardial infarction. For instance, Nissen and colleagues reported 43% and 28% increased odds for myocardial infarction in their 2007 and 2010 meta-analyses, respectively.⁵

²¹ Our analysis also suggests an increased risk of myocardial infarction, albeit with less certainty because the 95% confidence interval just crosses 1.0 in most of the analyses. Furthermore, across different analytic approaches, odds ratios ranged from 1.07 to 1.30, with the most attenuated estimates

occurring by combining summary level data with IPD.

Clinical and regulatory implications

Given the large number of patients treated for diabetes, drugs with even modest cardiovascular risks can have major public health implications.⁵³ Almost 20 years after rosiglitazone was approved, uncertainties still exist among patients, clinicians, and policy makers about the effect of the drug on the risk of myocardial infarction. Consistent with previous studies,^{5 21 38} our meta-analyses suggest modest increases in myocardial infarction risk. Rosiglitazone, which along with pioglitazone is one of two currently marketed thiazolidinediones in the US, has been suspended by the European Medicines Agency and is no longer recommended for use in the US.¹⁵ In the US, pioglitazone, which has also been associated with an increased risk of heart failure, is the preferred treatment option.¹⁵ According to the PROACTIVE (PROspective pioglitAzone Clinical Trial In macro-Vascular Events) trial, pioglitazone does not have the same cardiovascular risks as rosiglitazone.^{54 55} Additionally, a recent meta-analysis of 16 observational studies found that rosiglitazone was associated with higher risk of congestive heart failure, myocardial infarction, and death compared with pioglitazone.⁵⁶

Our study highlights the need for independent evidence assessment to promote transparency and ensure confidence in approved therapeutics, and postmarket surveillance that tracks known and unknown risks and benefits. As a result of the rosiglitazone controversy, the FDA issued guidance for industry in 2008 that outlined requirements for demonstrating the cardiovascular safety for new drugs developed for glycemic management in patients with type 2 diabetes.³⁴ In particular, the

Table 5 | Rosiglitazone meta-analyses for heart failure

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	P value	No of trials
Peto (fixed)						
IPD only	Included	Excluded	None	OR 1.66 (1.24 to 2.22)	0.001	26
IPD+RECORD	Included	Excluded		OR 1.80 (1.46 to 2.22)	0.000	27
Mantel-Haenszel (fixed)						
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.60 (1.20 to 2.14)	0.002	26
				RR 1.57 (1.18 to 2.08)	0.002	27
IPD+RECORD	Included	Excluded		OR 1.78 (1.44 to 2.20)	0.000	27
				RR 1.74 (1.42 to 2.14)	0.000	27
IPD only	Included	Included		OR 1.56 (1.17 to 2.07)	0.002	33
				RR 1.53 (1.16 to 2.02)	0.003	33
IPD+RECORD	Included	Included		OR 1.75 (1.42 to 2.16)	0.000	34
				RR 1.71 (1.40 to 2.10)	0.000	34
Dersimonian and Laird (random)						
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.54 (1.14 to 2.09)	0.005	26
				RR 1.52 (1.14 to 2.03)	0.004	26
IPD+RECORD	Included	Excluded		OR 1.75 (1.41 to 2.18)	0.000	27
				RR 1.72 (1.39 to 2.11)	0.000	27
IPD only	Included	Included		OR 1.50 (1.12 to 2.01)	0.007	33
				RR 1.48 (1.12 to 1.97)	0.006	33
IPD+RECORD	Included	Included		OR 1.72 (1.39 to 2.13)	0.000	34
				RR 1.69 (1.37 to 2.08)	0.000	34
Mantel-Haenszel (fixed)						
IPD only	Included	Excluded	Treatment arm correction	OR 1.65 (1.23 to 2.20)	0.001	26
				RR 1.61 (1.21 to 2.14)	0.001	26
IPD+RECORD	Included	Excluded		OR 1.81 (1.46 to 2.24)	0.000	27
				RR 1.77 (1.44 to 2.17)	0.000	27
IPD only	Included	Included		OR 1.62 (1.21 to 2.15)	0.001	33
				RR 1.59 (1.20 to 2.10)	0.001	33
IPD+RECORD	Included	Included		OR 1.79 (1.45 to 2.21)	0.000	34
				RR 1.75 (1.42 to 2.15)	0.000	34
Dersimonian and Laird (random)						
IPD only	Included	Excluded	Treatment arm correction	OR 1.58 (1.17 to 2.13)	0.003	26
				RR 1.55 (1.16 to 2.08)	0.003	26
IPD+RECORD	Included	Excluded		OR 1.77 (1.42 to 2.20)	0.000	27
				RR 1.73 (1.41 to 2.14)	0.000	27
IPD only	Included	Included		OR 1.55 (1.15 to 2.09)	0.004	33
				RR 1.53 (1.15 to 2.03)	0.004	33
IPD+RECORD	Included	Included		OR 1.75 (1.41 to 2.17)	0.000	34
				RR 1.72 (1.40 to 2.11)	0.000	34

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of heart failure events observed among total population of patients was as follows: IPD only, rosiglitazone population: 122 events among 11 837 patients; IPD only, control population: 80 events among 9319 patients; RECORD, rosiglitazone population: 119 events among 2226 patients; RECORD, control population: 61 events among 2232 patients.

document states that new diabetes drugs should rule out cardiovascular risk by demonstrating an upper bound of the two sided 95% confidence interval for the risk ratio less than 1.8 before approval for the composite end point of major adverse cardiovascular events. For upper bounds between 1.3 and 1.8, FDA might require additional postapproval trials.³⁴ Across multiple cardiovascular outcomes, we found that most of the upper bounds observed in the meta-analyses were above 1.3.

However, restrictions for rosiglitazone have actually been eased since 2013. The FDA determined that REMS were no longer necessary and that the benefits of rosiglitazone outweighed the risk.¹⁰ While evidence suggests that the 2008 FDA guidance has increased the amount of cardiovascular evidence generated, uncertainties remain about the design and timing of postapproval studies, and whether the information generated will be available to the

public.⁵⁷ Furthermore, in 2018, a Endocrinologic and Metabolic Drugs Advisory Committee meeting discussed the value of FDA's 2008 guidance, including the upper bounds of the two sided 95% confidence interval for the estimated risk ratio before approval.⁵⁸ Whether any changes will be made as a result of the recommendations from the committee members is currently unclear.

Promoting clinical trial transparency, data sharing initiatives, and role of IPD in meta-analyses of drug safety

Rosiglitazone provides an ideal case to assess the impact of using IPD for safety related meta-analyses that examine relatively rare adverse events. Previous studies have consistently observed incomplete safety reporting in randomized trials, with some estimates suggesting that less than 50% of randomized trials adequately report clinical adverse effects.⁵⁹ Further-

more, concerns have been raised about discrepancies in the reporting of outcomes across different sources of data,^{37 42} with registries (eg, ClinicalTrials.gov) having poorer reporting quality than clinical summary reports.⁶⁰ Clinical summary reports provide detailed information on study design and outcomes, and are often believed to be sufficient for systematic reviews.⁶¹

However, we identified more myocardial infarctions and fewer cardiovascular deaths in the IPD compared with the numbers previously reported based on clinical summary reports. Among 29 trials for which IPD were available and which were included in previous meta-analyses using GSK's summary level data, 26 had more identifiable myocardial infarctions and five had fewer

Table 6 | Rosiglitazone meta-analyses for cardiovascular related deaths

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	No of trials
Peto (fixed)					
IPD only	Included	Excluded	None	OR 1.34 (0.60 to 2.98)	15
IPD+RECORD	Included	Excluded		OR 1.11 (0.76 to 1.62)	16
IPD+summary	Included	Excluded		OR 1.23 (0.77 to 1.98)	33
IPD+summary+RECORD	Included	Excluded		OR 1.13 (0.82 to 1.55)	34
Mantel-Haenszel (fixed)					
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.13 (0.58 to 2.21)	15
				RR 1.13 (0.58 to 2.20)	15
IPD+RECORD	Included	Excluded		OR 1.07 (0.75 to 1.54)	16
				RR 1.07 (0.75 to 1.53)	16
IPD+summary	Included	Excluded		OR 1.10 (0.73 to 1.65)	33
				RR 1.09 (0.73 to 1.64)	33
IPD+summary+RECORD	Included	Excluded		OR 1.08 (0.80 to 1.44)	34
				RR 1.07 (0.80 to 1.44)	34
IPD only	Included	Included		OR 0.97 (0.56 to 1.66)	33
				RR 0.97 (0.57 to 1.65)	33
IPD+RECORD	Included	Included		OR 1.02 (0.73 to 1.42)	34
				RR 1.02 (0.73 to 1.41)	34
IPD+summary	Included	Included		OR 1.00 (0.75 to 1.32)	136
				RR 1.00 (0.76 to 1.32)	136
IPD+summary+RECORD	Included	Included		OR 1.01 (0.80 to 1.28)	137
				RR 1.01 (0.80 to 1.27)	137
Dersimonian and Laird (random)					
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.15 (0.55 to 2.41)	15
				RR 1.15 (0.55 to 2.39)	15
IPD+RECORD	Included	Excluded		OR 1.08 (0.64 to 1.56)	16
				RR 1.08 (0.75 to 1.55)	16
IPD+summary	Included	Excluded		OR 1.12 (0.72 to 1.74)	33
				RR 1.12 (0.72 to 1.73)	33
IPD+summary+RECORD	Included	Excluded		OR 1.08 (0.80 to 1.47)	34
				RR 1.08 (0.80 to 1.46)	34
IPD only	Included	Included		OR 0.95 (0.53 to 1.69)	33
				RR 0.95 (0.54 to 1.68)	33
IPD+RECORD	Included	Included		OR 1.01 (0.72 to 1.43)	34
				RR 1.01 (0.72 to 1.42)	34
IPD+summary	Included	Included		OR 1.00 (0.74 to 1.33)	136
				RR 1.00 (0.74 to 1.32)	136
IPD+summary+RECORD	Included	Included		OR 1.01 (0.79 to 1.29)	137
				RR 1.01 (0.80 to 1.28)	137
Mantel-Haenszel (fixed)					
IPD only	Included	Excluded	Treatment arm correction	OR 1.23 (0.62 to 2.42)	15
				RR 1.22 (0.62 to 2.42)	15
IPD+RECORD	Included	Excluded		OR 1.10 (0.77 to 1.58)	16
				RR 1.10 (0.77 to 1.57)	16
IPD+summary	Included	Excluded		OR 1.17 (0.77 to 1.77)	33
				RR 1.17 (0.77 to 1.77)	33
IPD+summary+RECORD	Included	Excluded		OR 1.11 (0.83 to 1.50)	34
				RR 1.11 (0.83 to 1.49)	34
IPD only	Included	Included		OR 1.15 (0.66 to 1.99)	33
				RR 1.14 (0.66 to 1.99)	33
IPD+RECORD	Included	Included		OR 1.09 (0.77 to 1.52)	34
				RR 1.08 (0.78 to 1.52)	34
IPD+summary	Included	Included		OR 1.08 (0.81 to 1.44)	136
				RR 1.08 (0.81 to 1.43)	136
IPD+summary+RECORD	Included	Included		OR 1.07 (0.84 to 1.36)	137
				RR 1.07 (0.85 to 1.35)	137

Continued

Table 6 | Continued

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	No of trials
Dersimonian and Laird (random)					
IPD only	Included	Excluded	Treatment arm correction	OR 1.26 (0.58 to 2.72)	15
				RR 1.26 (0.59 to 2.70)	15
IPD+RECORD	Included	Excluded		OR 1.10 (0.76 to 1.59)	16
				RR 1.10 (0.76 to 1.58)	16
IPD+summary	Included	Excluded		OR 1.19 (0.75 to 1.88)	33
				RR 1.18 (0.75 to 1.86)	33
IPD+summary+RECORD	Included	Excluded		OR 1.11 (0.82 to 1.52)	34
				RR 1.11 (0.82 to 1.51)	34
IPD only	Included	Included		OR 1.15 (0.63 to 2.10)	33
				RR 1.15 (0.63 to 2.09)	33
IPD+RECORD	Included	Included		OR 1.08 (0.77 to 1.54)	34
				RR 1.08 (0.77 to 1.53)	34
IPD+summary	Included	Included		OR 1.08 (0.80 to 1.45)	136
				RR 1.08 (0.80 to 1.45)	136
IPD+summary+RECORD	Included	Included		OR 1.07 (0.84 to 1.37)	137
				RR 1.07 (0.84 to 1.36)	137

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of cardiovascular related deaths observed among total population of patients was as follows: IPD only, rosiglitazone population: 15 events among 11 837 patients; IPD only, control population: 10 events among 9319 patients; RECORD, rosiglitazone population: 44 events among 2226 patients; RECORD, control population: 42 events among 2232 patients; summary, rosiglitazone population: 26 events among 12 183 patients; summary, control population: 20 events among 10 589 patients.

cardiovascular related deaths in the IPD compared with the GSK summary level data. Before CSDR was introduced, IPD from rosiglitazone trials conducted by GSK were not available to researchers, and only certain stakeholders had access to the data. Therefore, previous meta-analyses of rosiglitazone safety might not have included the data necessary to accurately classify all adverse events. Our study suggests that when evaluating drug safety and performing meta-analyses focused on safety, IPD might be necessary to accurately classify all adverse events. By including these data in research, patients, clinicians, and researchers would be able to make more informed decisions about the safety of interventions.^{25 62}

Numerous initiatives to promote open science and foster clinical trial data sharing have been developed over the last few years.^{25 31 32 63-67} In 2013, GSK launched CSDR, which contains over 1500 trials from more than a dozen major pharmaceutical companies, including Bayer, Novartis, and Roche.³³ Similarly, Supporting Open Access to Research, a partnership between Bristol-Myer Squibb and Duke Clinical Research Institute, provides access to Bristol-Myer Squibb trial data.⁶⁸ University based platforms also exist, including the Yale Open Data Access project, which has partnered with Johnson & Johnson, Medtronic, and SI-BONE.^{32 69 70} These platforms ensure that all shared data are deidentified, and they also require requestors to prespecify their research questions and methods. Furthermore, they employ a “trusted intermediary” approach, with independent review committees screening detailed proposals and making data sharing decisions. While there has already been a rapid shift towards a data sharing and transparency culture, further opportunities exist for industry, funders, and researchers to facilitate clinical trial data sharing.

Determining whether analytical approaches alter conclusions of adverse event meta-analyses

In addition to the implications of using IPD compared with summary level data, our study suggests that various statistical methods used to account for sparse adverse event data in meta-analyses might not drastically alter interpretations about rosiglitazone's risk. Across all outcomes, when trials with zero events in both arms were included after adding 0.5, risk estimates were attenuated towards the null. When a treatment arm continuity correction was used, the risk estimates increased. However, all 95% confidence intervals were broadly consistent and crossed the null odds ratio value of 1.0. Currently, no consensus exists on whether zero total event trials should be included in meta-analyses. For instance, the Cochrane handbook states that “the standard practice in meta-analyses of odds ratios and risk ratios is to exclude studies from the meta-analysis when there are no events in both arms,”⁷¹ because they do not contribute to the magnitude of effect.⁷² However, some methodologists argue that zero event total trials should be included in meta-analyses of sparse data because they use all potential data, lead to more precise estimates, and can avoid overestimating treatment effects.⁷³

While multiple methods and continuity correction factors can be included as sensitivity analyses, it is unclear which methods should be used across different situations.⁴⁵ In our study, we prioritized odds ratio approximations including single zero event trials with a 0.5 constant continuity correction because this is the standard approach used in meta-analytical software. Meanwhile, Sweeting and colleagues recommend using a treatment arm continuity correction, which adds a factor of the reciprocal of the opposite treatment arm to the zero event cells instead of a constant continuity correction, especially when treatment

Table 7 | Rosiglitazone meta-analyses for non-cardiovascular related deaths

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	No of trials
Peto (fixed)					
IPD only	Included	Excluded	None	OR 1.42 (0.72 to 2.81)	16
IPD+RECORD	Included	Excluded	None	OR 0.85 (0.66 to 1.10)	17
Mantel-Haenszel (fixed)					
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.18 (0.64 to 2.17)	16
				RR 1.18 (0.65 to 2.15)	16
				OR 0.84 (0.65 to 1.08)	17
IPD+RECORD	Included	Excluded		RR 0.84 (0.66 to 1.08)	17
IPD only	Included	Included		OR 1.04 (0.62 to 1.73)	33
				RR 1.04 (0.63 to 1.71)	33
IPD+RECORD	Included	Included		OR 0.83 (0.65 to 1.06)	34
				RR 0.84 (0.66 to 1.06)	34
Dersimonian and Laird (random)					
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.18 (0.60 to 2.30)	16
				RR 1.18 (0.61 to 2.28)	16
				OR 0.83 (0.64 to 1.07)	17
IPD+RECORD	Included	Excluded		RR 0.83 (0.65 to 1.07)	17
IPD only	Included	Included		OR 1.01 (0.58 to 1.74)	33
				RR 1.01 (0.59 to 1.74)	33
IPD+RECORD	Included	Included		OR 0.82 (0.64 to 1.05)	34
				RR 0.83 (0.65 to 1.05)	34
Mantel-Haenszel (fixed)					
IPD only	Included	Excluded	Treatment arm correction	OR 1.32 (0.71 to 2.45)	16
				RR 1.32 (0.71 to 2.44)	16
				OR 0.85 (0.66 to 1.10)	17
IPD+RECORD	Included	Excluded		RR 0.86 (0.67 to 1.10)	17
IPD only	Included	Included		OR 1.22 (0.73 to 2.06)	33
				RR 1.22 (0.73 to 2.05)	33
IPD+RECORD	Included	Included		OR 0.86 (0.67 to 1.10)	34
				RR 0.87 (0.68 to 1.10)	34
Dersimonian and Laird (random)					
IPD only	Included	Excluded	Treatment arm correction	OR 1.25 (0.63 to 2.50)	16
				RR 1.25 (0.63 to 2.48)	16
				OR 0.83 (0.64 to 1.08)	17
IPD+RECORD	Included	Excluded		RR 0.84 (0.65 to 1.07)	17
IPD only	Included	Included		OR 1.16 (0.66 to 2.04)	33
				RR 1.16 (0.66 to 2.03)	33
IPD+RECORD	Included	Included		OR 0.84 (0.65 to 1.08)	34
				RR 0.85 (0.66 to 1.08)	34

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of non-cardiovascular related deaths observed among total population of patients was as follows: IPD only, rosiglitazone population: 22 events among 11 837 patients; IPD only, control population: 13 events among 9319 patients; RECORD, rosiglitazone population: 91 events among 2226 patients; RECORD, control population: 116 events among 2232 patients.

groups are unbalanced.⁴⁵ Future meta-analyses that need to account for sparse data could benefit from performing multiple sensitivity analyses that compare the results across a number of commonly proposed methods. While these analyses might not always alter perceptions of safety, they could provide insight on the consistency of effect estimates.

For myocardial infarction and cardiovascular related deaths, effect estimates were attenuated towards the null when we included summary level data from publications, ClinicalTrials.gov, and clinical summary reports. Numerous study design characteristics exist that can potentially explain these results. Firstly, the meta-analysis by Nissen and colleagues in 2007, which resulted in an increased awareness of the risk of rosiglitazone, could have altered the types of patients who were recruited into subsequent trials, thereby minimizing potential cardiovascular adverse events.⁵

Secondly, different study design considerations in more recent trials, including treatment comparators, concurrent treatments, and patient populations, could have reduced the risk of adverse cardiovascular outcomes or minimized differences across the treatment arms. For instance, trials might have preferentially enrolled patients into rosiglitazone trials who were at lower cardiovascular risk. However, our post hoc subgroup analyses based on comparator type did not reveal any statistically significant interactions.

Thirdly, the studies for which IPD were not available were generally small, with high or unclear risk of bias, which could have biased the results. Although FDA draft guidance for industry on performing meta-analysis of randomized trials to evaluate drug safety emphasized the importance of prioritizing trial quality over quantity,⁷⁴ it might not always be clear which, if any, study characteristics actually influence the results of a meta-analysis. Considering that we observed

Table 8 | Rosiglitazone one stage meta-analyses

Outcome and data sources	Events/total population	Effect estimate (95% CI)	
		Fixed effect	Random study specific effects*
Composite outcome			
IPD	RSG: 274/11 837; control: 219/9319	1.39 (1.15 to 1.68)	1.39 (1.15 to 1.83)
Myocardial infarction			
IPD	RSG: 147/11 837; control: 133/9319	1.27 (1.00 to 1.64)	1.27 (1.00 to 1.92)
IPD+summary	RSG: 190/24 467; control: 173/20 372	1.20 (0.97 to 1.49)	1.20 (0.96 to 1.51)
Heart failure			
IPD	RSG: 122/11 837; control: 80/9319	1.64 (1.22 to 2.21)	1.64 (1.22 to 2.24)
Cardiovascular related deaths			
IPD	RSG: 15/11 837; control: 10/9319	1.25 (0.56 to 2.92)	1.25 (0.46 to 2.92)
IPD+summary	RSG: 41/24 020; control: 30/19 908	1.22 (0.76 to 1.98)	1.22 (0.74 to 1.98)
Non-cardiovascular related deaths			
IPD	RSG: 22/11 837; control: 13/9319	1.36 (0.69 to 2.84)	1.36 (0.61 to 2.83)
IPD=individual patient level data; RSG=rosiglitazone.			
*Simmonds and Higgin's model with random study specific effects.			

IPD=individual patient level data; RSG=rosiglitazone.

*Simmonds and Higgin's model with random study specific effects.

different results when including various data sources, our findings highlight the importance of presenting and discussing potential differences across all possible data sources.

Limitations

Analytical limitations

Firstly, we conducted a large number of prespecified analyses, and certain analyses had a relatively low number of events, which could have reduced the statistical power. Furthermore, the low number of events suggests that trials might have preferentially enrolled lower risk patients, the findings from which could be less generalizable to high risk patients treated in real world practice. Because multiple testing and lower power in meta-analyses can be problematic, we did not focus on statistical significance and presented the results from all analyses to minimize the risk of selective reporting. Secondly, and relatedly, our meta-analyses might also be limited by the designs of the trials. In particular, eligible trials were generally designed to evaluate short term efficacy, and not long term cardiovascular safety, and seemingly preferentially enrolled lower risk patients. Cardiovascular risk might not be evident with short term use, and our sample might not represent the true long term benefit-risk profile of rosiglitazone.

Thirdly, we selected only two commonly used continuity corrections to account for sparse data. Although many other methods have been proposed, currently no consensus exists on whether or how meta-analysis should include information from trials with zero events in either one or all study arms.⁴⁴ Future evaluations could explore the impact of performing more advanced analyses that account for sparse data, such as Poisson or zero inflated negative binomial models.^{17 49}

Fourthly, we abstracted and classified the adverse events across treatment arms and focused on comparing the results from different two stage meta-analytical approaches. Although we conducted a series of one stage sensitivity analyses, we did not conduct time to event analyses. There were a number of reasons for not conducting time to event analyses, which we discussed

before conducting the study. Although IPD can be used to conduct time to event analyses, we would not have been able to synthesize the data from studies with and without IPD. Because the rosiglitazone trials were not specifically designed to evaluate long term safety, we did not believe that hazard ratios would be particularly informative. It is possible that analyses of hazard ratios could alter some of the observed estimates. However, summary odds ratios do not have an actual timepoint that they relate to, and when we conducted a series of post hoc subgroup analyses, we found no statistical difference between odds ratios across clinical trials categorized by treatment duration. Future evaluations could consider additional one stage and time to event analyses, with different model assumptions and adjustments for prognostic factors.

Finally, we did not analyze whether certain characteristics, including age, sex, and race, influenced study heterogeneity because these variables are difficult to adjust for when combining summary level and IPD data. With only five studies classified as having a low risk of bias, we were also unable to conduct additional sensitivity analyses that evaluated the impact of risk of bias.

Data source limitations

We only included published articles that mentioned specific adverse events of interest or disclosed that serious adverse events were not observed. Additionally, we did not request IPD from investigators of trials for which we had access to summary level data. IPD are commonly not made available for small, investigator initiated trials more than a decade old that are probably in older formats.⁷⁵ Although we contacted corresponding authors to clarify potential uncertainties, failure to mention a particular outcome does not necessarily imply that there were no such events in the study.³⁷ Furthermore, we could have missed certain adverse events, including those unreported by patients, clinicians, and trial authors, which increases the potential for publication and data availability biases. Trials for which IPD were available used different terminologies with different levels of specificity. Although multiple reviewers evaluated the

lists of trial adverse events, it is possible that certain outcomes could have been misclassified or missed altogether. Finally, as noted earlier, our study could be limited by the quality of the individual studies, most of which did not have IPD available, had small sample sizes, and were classified as having a high risk of bias. Nevertheless, our results were consistent across many analyses that make use of different combinations of data sources.

Conclusion

When we limited our analysis to trials for which IPD were available, rosiglitazone use was associated with an increased cardiovascular risk, probably owing to heart failure events. However, clinical uncertainties about interpreting the cardiovascular risk of rosiglitazone might not be fully resolved because of different magnitudes of myocardial infarction risk that were attenuated when summary level data were used in addition to IPD. Different analytical approaches to account for sparse data did not alter the conclusions across analyses, however multiple sensitivity analyses provided insight into the consistency of effect estimates. Finally, among trials for which IPD were available, more myocardial infarctions and fewer cardiovascular deaths were reported in IPD compared with summary level data reported in publications, clinical summary reports, and on ClinicalTrials.gov. This finding suggests that IPD might be necessary to accurately classify all adverse events when performing meta-analyses focused on safety.

AUTHOR AFFILIATIONS

¹Department of Environmental Health Sciences, Yale School of Public Health, 60 College Street, New Haven, CT 06510, USA

²Collaboration for Research Integrity and Transparency, Yale School of Medicine, New Haven, CT, USA

³Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, CT, USA

⁴New York University School of Medicine, New York, NY, USA

⁵Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

⁶Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, USA

⁷Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA

⁸Section of Cardiovascular Medicine and the National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

⁹Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA

¹⁰Section of General Medicine and the National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

Preprint: <https://www.medrxiv.org/content/10.1101/19000463v1>.

We thank Mary Hughes and Vermetha Polite of the Cushing/Whitney Medical Library at Yale for technical support; they are employees of Yale University and did not receive additional compensation for this work, nor do they have competing interests to disclose.

Contributors: JDW, DC, HMK, and JSR conceived and designed this study. JDW, KW, ADZ, DC, and HKGN acquired the data. JDW conducted the statistical analysis and drafted the manuscript. All authors participated in the interpretation of the data and critically revised the manuscript for important intellectual content. JDW and JSR had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JSR provided supervision. JDW and JSR are guarantors. The corresponding

author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This project was conducted as part of the Collaboration for Research Integrity and Transparency at Yale, funded by the Laura and John Arnold Foundation, which supports JDW, ADZ, and JSR. These funders played no role in the design of the study, analysis or interpretation of findings, or drafting the manuscript and did not review or approve the manuscript prior to submission. The authors assume full responsibility for the accuracy and completeness of the ideas presented.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the Laura and John Arnold Foundation for the submitted work. In the past 36 months, JDW received research support through the Meta Research Innovation Center at Stanford (METRICS) from the Laura and John Arnold Foundation and through the Yale-Male Clinic Center for Excellence in Regulatory Science and Innovation (CERSI; U01FD005938); ADZ received research support through the Yale-Mayo Clinic CERSI (U01FD005938); MB is currently, or within the last four years has been, a consultant to Eli Lilly, Forest Laboratories, Glaxo, and Lundbeck, all on matters unrelated to the content of this manuscript; HMK received research support through Yale from Johnson & Johnson to develop methods of clinical trial data sharing, from Medtronic and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services to develop and maintain performance measures that are used for public reporting, received payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation, chairs a Cardiac Scientific Advisory Board for UnitedHealth, is a participant/participant representative of the IBM Watson Health Life Sciences Board, is a member of the Advisory Board for Element Science and the Physician Advisory Board for Aetna, and is the founder of Hugo, a personal health information platform; JSR received research support through Yale from Johnson & Johnson to develop methods of clinical trial data sharing, from Medtronic and the FDA to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services to develop and maintain performance measures that are used for public reporting, from the FDA to establish a CERSI at Yale University and the Mayo Clinic (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Agency for Healthcare Research and Quality (R01HS022882).

Ethical approval: Not required.

Data sharing: The summary level dataset will be made available through a publicly accessible repository on publication: <https://osf.io/4yvp2/>. Individual patient level data must be requested from GlaxoSmithKline through ClinicalStudyDataRequest.com

The lead authors (JDW and JSR) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant registered) have been explained.

Dissemination to participants and related patient and public communities: We will promote the dissemination of these results to the relevant patient communities; since no patients were recruited for this study, there are no plans to disseminate the results of the research to study participants.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

- 1 Pouwels KB, van Grootheest K. The rosiglitazone decision process at FDA and EMA. What should we learn? *Int J Risk Saf Med* 2012;24:73-80. doi:10.3233/JRS-2012-0559
- 2 Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. *N Engl J Med* 2010;363:1489-91. doi:10.1056/NEJMp1010788
- 3 Cohen D. Rosiglitazone: what went wrong? *BMJ* 2010;341:c4848. doi:10.1136/bmj.c4848
- 4 Nissen SE. The rise and fall of rosiglitazone. *Eur Heart J* 2010;31:773-6. doi:10.1093/eurheartj/ehq016
- 5 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007;356:2457-71. doi:10.1056/NEJMoa072761

- 6 Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. *N Engl J Med* 2007;356:2522-4. doi:10.1056/NEJMe078099
- 7 Rosen CJ. Revisiting the rosiglitazone story--lessons learned. *N Engl J Med* 2010;363:803-6. doi:10.1056/NEJMp1008233
- 8 Bloomgarden ZT. The Avandia debate. *Diabetes Care* 2007;30:2401-8. doi:10.2337/dc07-zb09
- 9 US Food and Drug Administration (FDA). FDA drug safety communication: updated Risk Evaluation and Mitigation Strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. 18 May 2011. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-risk-evaluation-and-mitigation-strategy-rems-restrict-access>.
- 10 McCarthy M. US regulators relax restrictions on rosiglitazone. *BMJ* 2013;347:f7144. doi:10.1136/bmj.f7144
- 11 Nissen SE. Setting the RECORD Straight. *JAMA* 2010;303:1194-5. doi:10.1001/jama.2010.333
- 12 Hickson RP, Cole AL, Dusetzina SB. Implications of removing rosiglitazone's black box warning and restricted access program on the uptake of thiazolidinediones and dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes. *J Manag Care Spec Pharm* 2019;25:72-9. doi:10.18553/jmcp.2019.25.1.072
- 13 Hampf C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the US, 2003-2012. *Diabetes Care* 2014;37:1367-74. doi:10.2337/dc13-2289
- 14 Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning--geographic variation in the use of rosiglitazone. *N Engl J Med* 2010;363:2081-4. doi:10.1056/NEJMp1011042
- 15 McCulloch DK. Thiazolidinediones in the treatment of diabetes mellitus. 2019. <https://www.uptodate.com/contents/thiazolidinediones-in-the-treatment-of-diabetes-mellitus>.
- 16 Bracken MB. Rosiglitazone and cardiovascular risk. *N Engl J Med* 2007;357:937-40. doi:10.1056/NEJMc071602
- 17 Cai T, Parast L, Ryan L. Meta-analysis for rare events. *Stat Med* 2010;29:2078-89. doi:10.1002/sim.3964
- 18 Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. *Ann Intern Med* 2007;147:578-81. doi:10.7326/0003-4819-147-8-200710160-00182
- 19 Friedrich JO, Beyene J, Adhikari NK. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. *BMC Res Notes* 2009;2:5. doi:10.1186/1756-0500-2-5
- 20 Mannucci E, Monami M, Marchionni N. Rosiglitazone and cardiovascular risk. *N Engl J Med* 2007;357:938-40.
- 21 Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch Intern Med* 2010;170:1191-201. doi:10.1001/archinternmed.2010.207
- 22 Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K, MUDS investigators. Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. *J Clin Epidemiol* 2019;113:20-7. doi:10.1016/j.jclinepi.2019.04.022
- 23 Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. *Arch Intern Med* 2009;169:1756-61. doi:10.1001/archinternmed.2009.306
- 24 Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;340:c221. doi:10.1136/bmj.c221
- 25 Ross JS, Krumholz HM. Ushering in a new era of open science through data sharing: the wall must come down. *JAMA* 2013;309:1355-6. doi:10.1001/jama.2013.1299
- 26 Institute of Medicine (IOM). *Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risks*. The National Academies Press, 2015.
- 27 Dahabreh IJ, Economopoulos K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone [correction in: *Clin Trials* 2008;5:559]. *Clin Trials* 2008;5:116-20. doi:10.1177/1740774508090212
- 28 Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. *BMC Med Res Methodol* 2007;7:5. doi:10.1186/1471-2288-7-5
- 29 Herbison P, Robertson MC, McKenzie JE. Do alternative methods for analysing count data produce similar estimates? Implications for meta-analyses. *Syst Rev* 2015;4:163. doi:10.1186/s13643-015-0144-x
- 30 Tian L, Cai T, Pfeiffer MA, Piankov N, Cremieux PY, Wei LJ. Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. *Biostatistics* 2009;10:275-81. doi:10.1093/biostatistics/kxn034
- 31 Munafo MR, Nosek BA, Bishop DVM, et al. A manifesto for reproducible science. *Nat Hum Behav* 2017;1. doi:10.1038/s41562-016-0021
- 32 Krumholz HM, Ross JS. A model for dissemination and independent analysis of industry data. *JAMA* 2011;306:1593-4. doi:10.1001/jama.2011.1459
- 33 Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. *N Engl J Med* 2013;369:475-8. doi:10.1056/NEJMs1302541
- 34 US Food and Drug Administration (FDA). Guidance for industry: diabetes mellitus -- evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetes>.
- 35 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535. doi:10.1136/bmj.b2535
- 36 Stewart LA, Clarke M, Rovers M, et al, PRISMA-IPD Development Group. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA* 2015;313:1657-65. doi:10.1001/jama.2015.3656
- 37 Mayo-Wilson E, Hutfless S, Li T, et al. Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol [corrections in: *Alzheimers Res Ther* 2018;10:20 and *Syst Rev* 2018;7:48]. *Syst Rev* 2015;4:143. doi:10.1186/s13643-015-0134-z
- 38 Mannucci E, Monami M, Di Bari M, et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. *Int J Cardiol* 2010;143:135-40. doi:10.1016/j.ijcard.2009.01.064
- 39 Grossetta Nardini HK, Wang L. The Yale MeSH Analyzer, New Haven, CT: Cushing/Whitney Medical Library. <http://mesh.med.yale.edu/>.
- 40 Clarivate Analytics. EndNote X9, Philadelphia, PA. <https://www.endnote.com/>.
- 41 Veritas Health Innovation. Covidence Systematic Review Software, Melbourne, Australia. <https://www.covidence.org/>.
- 42 Mayo-Wilson E, Li T, Fusco N, Dickersin K, MUDS investigators. Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study). *Res Synth Methods* 2018;9:2-12. doi:10.1002/jrsm.1277
- 43 MedDRA Hierarchy. <https://www.meddra.org/how-to-use/basics/hierarchy>.
- 44 Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med* 2007;26:53-77. doi:10.1002/sim.2528
- 45 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med* 2004;23:1351-75. doi:10.1002/sim.1761
- 46 Home PD, Pocock SJ, Beck-Nielsen H, et al, RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. *N Engl J Med* 2007;357:28-38. doi:10.1056/NEJMoa073394
- 47 DeAngelis CD, Fontanarosa PB. Ensuring integrity in industry-sponsored research: primum non nocere, revisited. *JAMA* 2010;303:1196-8. doi:10.1001/jama.2010.337
- 48 Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. *Lancet Oncol* 2016;17:e70-80. doi:10.1016/S1470-2045(15)00396-4
- 49 Böhning D, Mylona K, Kimber A. Meta-analysis of clinical trials with rare events. *Biom J* 2015;57:633-48. doi:10.1002/bimj.201400184
- 50 Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. *Stat Med* 2018;37:1059-85. doi:10.1002/sim.7588
- 51 Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med* 2017;36:855-75. doi:10.1002/sim.7141
- 52 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34. doi:10.1136/bmj.315.7109.629
- 53 Califf RM, Kramer JM. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. *Pharmacoepidemiol Drug Saf* 2008;17:782-6. doi:10.1002/pds.1617
- 54 Dormandy JA, Charbonnel B, Eckland DJ, et al, PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89. doi:10.1016/S0140-6736(05)67528-9
- 55 Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. *Drug Saf* 2009;32:187-202. doi:10.2165/00002018-200932030-00002

- 56 Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. *BMJ* 2011;342:d1309. doi:10.1136/bmj.d1309
- 57 Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a *Diabetes Care* editors' expert forum. *Diabetes Care* 2018;41:14-31. doi:10.2337/dci17-0057
- 58 US Food and Drug Administration (FDA). FDA background document: endocrinologic and metabolic drugs advisory committee meeting (October 24-25, 2018). <https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-24-25-2018-meeting-endocrinologic-and-metabolic-drugs-advisory-committee-meeting>.
- 59 Ioannidis JP, Lau J. Improving safety reporting from randomised trials. *Drug Saf* 2002;25:77-84. doi:10.2165/00002018-200225020-00002
- 60 Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. *BMJ* 2012;344:d8141. doi:10.1136/bmj.d8141
- 61 Mayo-Wilson E, Li T, Fusco N, et al. Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. *J Clin Epidemiol* 2017;91:95-110. doi:10.1016/j.jclinepi.2017.07.014
- 62 Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. *Lancet* 2014;383:166-75. doi:10.1016/S0140-6736(13)62227-8
- 63 Naudet F, Sakarovitch C, Janiaud P, et al. Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in *The BMJ* and *PLOS Medicine*. *BMJ* 2018;360:k400. doi:10.1136/bmj.k400
- 64 Platt R, Ramsberg J. Challenges for sharing data from embedded research. *N Engl J Med* 2016;374:1897. doi:10.1056/NEJMc1602016
- 65 Kalager M, Adami HO, Bretthauer M. Recognizing data generation. *N Engl J Med* 2016;374:1898. doi:10.1056/NEJMc1603789
- 66 Devereaux PJ, Guyatt G, Gerstein H, Connolly S, Yusuf S, International Consortium of Investigators for Fairness in Trial Data Sharing. Toward fairness in data sharing. *N Engl J Med* 2016;375:405-7. doi:10.1056/NEJMp1605654
- 67 Haug CJ. Whose data are they anyway? Can a patient perspective advance the data-sharing debate? *N Engl J Med* 2017;376:2203-5. doi:10.1056/NEJMp1704485
- 68 Pencina MJ, Louzao DM, McCourt BJ, et al. Supporting open access to clinical trial data for researchers: the Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. *Am Heart J* 2016;172:64-9. doi:10.1016/j.ahj.2015.11.002
- 69 Ross JS, Waldstreicher J, Bamford S, et al. Overview and experience of the YODA Project with clinical trial data sharing after 5 years. *Sci Data* 2018;5:180268. doi:10.1038/sdata.2018.268
- 70 Krumholz HM, Waldstreicher J. The Yale Open Data Access (YODA) Project--a mechanism for data sharing. *N Engl J Med* 2016;375:403-5. doi:10.1056/NEJMp1607342
- 71 Higgins JPT, Deeks JJ, Altman DG (eds). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (eds), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. <https://handbook.cochrane.org/>.
- 72 Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. *Stat Med* 1991;10:1665-77. doi:10.1002/sim.4780101105
- 73 Ren Y, Lin L, Lian Q, Zou H, Chu H. Real-world performance of meta-analysis methods for double-zero-event studies with dichotomous outcomes using the Cochrane Database of Systematic Reviews. *J Gen Intern Med* 2019;34:960-8. doi:10.1007/s11606-019-04925-8
- 74 US Food and Drug Administration (FDA). Guidance for industry: meta-analyses of randomized controlled clinical trials to evaluate the safety of human drugs or biological products. 2018. <https://www.fda.gov/media/117976/download>
- 75 Veroniki AA, Ashoor HM, Le SPC, et al. Retrieval of individual patient data depended on study characteristics: a randomized controlled trial. *J Clin Epidemiol* 2019;113:176-88. doi:10.1016/j.jclinepi.2019.05.031

Web appendix: Supplementary appendix

Web table: Updated effect estimates from meta-analyses of the cardiovascular risk associated with rosiglitazone